The field of immunochemistry is now mature, and yet companies continue to develop new immunoassay instruments and platforms to further improve sensitivity, to make multiplexing possible, to miniaturize the platforms for point-of-care, and to identify and develop assays for novel biomarkers, further expanding the potential of immunoassays for the future.

As labs consolidate, the immunochemistry analyzers market relies on instrument replacements to generate the needed revenue. Nearly all manufacturers rely on key strategies, such as offering replacements for old clinical chemistry and immunochemistry systems or acquiring clients from other vendors. Competition is stiffening as most vendors face difficulties increasing their customer base.

Consequently, market participants are expected to continue infectious disease immunoassay product development and menu expansion.

Indian Market Dynamics

The Indian immunochemistry instruments and reagents market in 2014 is estimated at Rs.845 crore, with reagents continuing to command a 90 percent share. ELISA kits contributed an additional Rs.230 crore and rapid tests Rs.185 crore in 2014.

The leading players include Roche and Abbot; Siemens and J Mitra; and bioMérieux, Tulip, Bio Rad, Ortho, Beckman Coulter, and Transasia. Agappe also has some presence in this segment.

Siemens bagged the order from AIIMS for its requirement for instruments for all six institutes (being closed systems, it reportedly supplied the systems at a unit price of Rs.1). Snibe is making inroads in its distribution network with its Maglumi series. With a competitively priced, comprehensive test menu of 113 parameters, including thyroid, tumor markers, and cardiac markers, the systems are finding popularity with doctors, clinicians, and technicians in their laboratories.

This year, the vendor emphasis has been on margins and profitability. The buyers have over the last couple of years become more discerning, laying more emphasis on quality rather than on just pricing.

Global Scenario

The global immunochemistry instruments and reagents market is expected to reach USD 24.5 billion by 2019 from USD 17.3 billion in 2014, growing at a CAGR of 7.2 percent from 2014 to 2019. There is a rising focus on biomarker development across the globe as they help in detection of various diseases in their initial stage. Immunochemistry plays a crucial role in the development of biomarkers, thus with the growing demand of biomarkers, the market for immunochemistry instruments and reagents will also flourish. Furthermore, government support in terms of funds and grants has also provided much needed impetus to this market. Moreover, increasing focus on drug monitoring and growing incidences of various diseases are other factors driving growth. In addition to this, technological advancement due to which automated and more accurate instruments are present is another major factor propelling growth. However, factors such as stringent regulations for the development and launch of immunochemistry products and low adoption rate of automated immunochemistry products in developing economies due to high cost can hinder the growth of the market in coming years.

Way Forward

The key challenge when building on an installed base is the high cost associated with transition. Even when dissatisfied, most lab managers endure outdated instruments to avoid resource-intensive issues, such as the purchase process, staff retraining, protocol standardization, and data management system reevaluation. As labs consolidate, the immunochemistry analyzer market relies on instrument replacements to generate the needed revenue. Nearly all manufacturers rely on key strategies, such as offering replacements for old clinical chemistry and immunochemistry systems or acquiring clients from other vendors. Competition is stiffening as most vendors face difficulties increasing their customer base. The future will see CLIA as a growing analyzer segment with tremendous focus on areas, such as infectious disease testing, and autoimmune and oncology segments. The market is moving toward multiparametric assays, and many companies are exploring the use of multiplex technologies using protein and peptide arrays for autoimmune diagnostics.

Indian Market Dynamics is based on market research conducted by Medical Buyer in March 2015


 

randox

Digital version